Companies

Centers for Medicare & Medicaid Services (CMS)

The Centers for Medicare & Medicaid Services (CMS) is a U.S. government agency that administers programs and policies related to Medicare and Medicaid. The available materials show its role in coverage and payment models, expanding digital health programs, overseeing certain providers, and contracting with companies to evaluate prior authorization requests under the WISeR model.

The Centers for Medicare & Medicaid Services (CMS) is the U.S. government agency that administers the WISeR model and contracts with companies to evaluate prior authorization requests. The sources also describe CMS as an agency that establishes coverage and payment policies and manages pilot programs related to health care.

Roles and policies described in the sources

  • Prior authorization: CMS administers the WISeR model, which uses artificial intelligence tools to assist contracted companies in evaluating prior authorization requests for certain Medicare services. The published documents mention complaints about delays, denials, and technical problems, while CMS says that a qualified physician must review denials.
  • Digital health: CMS expanded the ACCESS pilot program to include additional chronic conditions, with monthly payments linked to patient outcomes, and connected the program to the TEMPO pathway for collecting real-world use data on certain digital health technologies.
  • Coverage of medical procedures: CMS issued a final national decision expanding Medicare coverage of TAVR to include patients with severe asymptomatic aortic stenosis, while continuing to collect evidence for this group.
  • Payment and laboratory testing: CMS proposed reducing Medicare payments for approximately 775 tests beginning in 2027, according to the source material, as part of implementing a mechanism associated with the PAMA law.
  • Oversight of equipment suppliers: A report by the Office of Inspector General discussed the need for Medicare Advantage plans to strengthen oversight of medical equipment suppliers and recommended using the exclusion list more consistently and increasing verification.

What the available materials do not establish

  • The available materials do not provide a comprehensive profile of CMS’s structure, leadership, or all of its programs.
  • The sources do not determine the final outcomes of legislative proposals concerning laboratory payments.
  • The available evidence is insufficient to assess CMS’s overall performance or rank the agency relative to others.